Last Price$58.60.7%
Market Cap$29.1B
P/EBITDA LTM
5.3x
5Y avg
9.6x
Medical - Healthcare Plans industry
median
6.0x
Stock quality & Intrinsic value
5/10
23.0% undervalued
Centene Corporation P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 11.7x | (1,525.8x) | 15.6x | 6.9x | 4.8x | 5.8x | 8.0x | 19.4x | 11.1x | 13.3x | 10.1x | 7.9x | 9.1x | 13.2x | 10.1x | 7.2x | 16.2x | 9.7x | 7.0x | 5.3x |
Overvalued or undervalued?
Check the intrinsic value for CNC
and see if it's the right time to invest.
Centene Corporation (CNC) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Centene CorporationCNC
5.3x
5.9%
27.4%
2.0%
Median Peer Set
7.7x
8.9%
(18.9%)
1.2%
Oscar Health, Inc.OSCR
41.7x
56.5%
N/A
0.3%
UnitedHealth Group IncorporatedUNH
18.3x
8.9%
(35.7%)
3.6%
Humana Inc.HUM
9.2x
10.7%
(50.1%)
1.0%
Molina Healthcare, Inc.MOH
9.2x
19.3%
9.2%
2.9%
Cigna CorporationCI
7.7x
8.4%
(18.9%)
2.6%
CVS Health CorporationCVS
6.0x
4.2%
(43.6%)
1.2%
Elevance Health Inc.ELV
2.1x
3.2%
(0.0%)
3.4%
Alignment Healthcare, Inc.ALHC
(40.1x)
27.2%
(4.8%)
(8.1%)
Clover Health Investments, Corp.CLOV
(42.6x)
(41.5%)
(31.3%)
(10.5%)
CNC key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,505.9 50.4% | 2,279.0 51.3% | 2,919.3 28.1% | 3,364.5 15.3% | 4,102.9 21.9% | 4,448.3 8.4% | 5,340.6 20.1% | 8,667.6 62.3% | 10,863.3 25.3% | 16,560.0 52.4% | 22,760.0 37.4% | 40,607.0 78.4% | 48,382.0 19.1% | 60,116.0 24.3% | 74,639.0 24.2% | 111,115.0 48.9% | 125,982.0 13.4% | 144,547.0 14.7% | 153,999.0 6.5% | 163,071.0 5.9% |
| Cost of Goods Sold (COGS) | 1,232.8 | 1,880.5 | 2,385.9 | 2,697.3 | 3,450.2 | 3,743.4 | 4,402.9 | 7,962.1 | 9,654.8 | 14,656.0 | 20,014.0 | 35,063.0 | 42,581.0 | 51,695.0 | 65,796.0 | 95,899.0 | 111,783.0 | 127,891.0 | 122,458.0 | 128,436.0 |
% margin | 273.1 18.1% | 398.5 17.5% | 533.4 18.3% | 667.3 19.8% | 652.7 15.9% | 704.9 15.8% | 937.7 17.6% | 705.5 8.1% | 1,208.6 11.1% | 1,904.0 11.5% | 2,746.0 12.1% | 5,544.0 13.7% | 5,801.0 12.0% | 8,421.0 14.0% | 8,843.0 11.8% | 15,216.0 13.7% | 14,199.0 11.3% | 16,656.0 11.5% | 31,541.0 20.5% | 34,635.0 21.2% |
| Operating Expenses | 193.9 | 427.4 | 479.3 | 535.7 | 514.5 | 547.8 | 747.4 | 704.6 | 931.1 | 1,440.0 | 2,041.0 | 4,284.0 | 4,602.0 | 6,963.0 | 6,791.0 | 12,062.0 | 10,936.0 | 13,020.0 | 28,611.0 | 31,460.0 |
| Research & Development Expenses (R&D) | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Selling, General & Administrative Expenses (SG&A) | 193.9 | 346.3 | 399.7 | 444.7 | 514.5 | 547.8 | 587.0 | 704.6 | 931.1 | 1,440.0 | 2,041.0 | 4,137.0 | 4,446.0 | 6,752.0 | 6,533.0 | 11,343.0 | 10,166.0 | 11,589.0 | 12,563.0 | 12,400.0 |
% margin | 79.2 5.3% | (28.9) (1.3%) | 54.1 1.9% | 131.6 3.9% | 138.1 3.4% | 157.1 3.5% | 190.3 3.6% | (27.1) (0.3%) | 277.4 2.6% | 464.0 2.8% | 705.0 3.1% | 1,260.0 3.1% | 1,199.0 2.5% | 1,458.0 2.4% | 1,781.0 2.4% | 3,082.0 2.8% | 3,263.0 2.6% | 3,636.0 2.5% | 2,930.0 1.9% | 3,175.0 1.9% |
| Interest Income | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 443.0 | 376.0 | 665.0 | 665.0 | 0.0 | 0.0 |
| Interest Expense | 4.0 | 10.6 | 15.6 | 16.7 | 16.3 | 18.0 | 20.3 | 20.5 | 27.0 | 35.0 | 43.0 | 217.0 | 255.0 | 343.0 | 412.0 | 728.0 | 665.0 | 665.0 | 725.0 | 702.0 |
| Pre-tax Income | 85.9 | (21.7) | 63.6 | 136.6 | 137.5 | 154.3 | 174.9 | (11.6) | 268.9 | 457.0 | 697.0 | 1,157.0 | 1,134.0 | 1,368.0 | 1,782.0 | 2,773.0 | 1,813.0 | 1,962.0 | 3,598.0 | 4,257.0 |
% effective tax rate | 30.2 35.2% | 22.0 (101.5%) | 22.4 35.1% | 52.4 38.4% | 48.8 35.5% | 59.9 38.8% | 66.5 38.0% | (0.3) 2.8% | 107.1 39.8% | 196.0 42.9% | 339.0 48.6% | 599.0 51.8% | 326.0 28.7% | 474.0 34.6% | 473.0 26.5% | 979.0 35.3% | 477.0 26.3% | 760.0 38.7% | 899.0 25.0% | 963.0 22.6% |
% margin | 55.6 3.7% | (43.6) (1.9%) | 73.4 2.5% | 83.5 2.5% | 83.7 2.0% | 94.8 2.1% | 111.2 2.1% | 1.9 0.0% | 165.1 1.5% | 271.0 1.6% | 355.0 1.6% | 562.0 1.4% | 828.0 1.7% | 900.0 1.5% | 1,321.0 1.8% | 1,808.0 1.6% | 1,347.0 1.1% | 1,202.0 0.8% | 2,702.0 1.8% | 3,305.0 2.0% |
| EPS | 0.33 | (0.25) | 0.42 | 0.48 | 0.49 | 0.49 | 0.56 | 0.01 | 0.76 | 1.17 | 1.49 | 1.76 | 2.40 | 2.31 | 3.19 | 3.17 | 2.31 | 2.09 | 4.97 | 6.33 |
| Diluted EPS | 0.31 | (0.25) | 0.41 | 0.47 | 0.47 | 0.47 | 0.53 | 0.01 | 0.74 | 1.13 | 1.44 | 1.72 | 2.35 | 2.26 | 3.14 | 3.12 | 2.28 | 2.07 | 4.95 | 6.31 |
% margin | 102.9 6.8% | 9.6 0.4% | 81.9 2.8% | 167.0 5.0% | 182.1 4.4% | 224.3 5.0% | 248.7 4.7% | 66.8 0.8% | 354.6 3.3% | 581.0 3.5% | 851.0 3.7% | 1,652.0 4.1% | 1,750.0 3.6% | 2,206.0 3.7% | 2,837.0 3.8% | 4,760.0 4.3% | 3,954.0 3.1% | 4,058.0 2.8% | 5,616.0 3.6% | 6,200.0 3.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Centene Corporation's P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 5.3x, based on the financial report for Dec 30, 2024 (Q4’2024). The average annual P/EBITDA LTM for Centene Corporation have been 9.2x over the past three years, and 10.1x over the past five years.
2) Is Centene Corporation's P/EBITDA LTM Good?
As of today, Centene Corporation's P/EBITDA LTM is 5.3x, which is lower than industry median of 6.0x. It indicates that Centene Corporation's P/EBITDA LTM is Good.